Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Iovance Biotherapeutics Inc (IOVA)

Iovance Biotherapeutics Inc (IOVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,262,853
  • Shares Outstanding, K 279,833
  • Annual Sales, $ 1,190 K
  • Annual Income, $ -444,040 K
  • 60-Month Beta 0.63
  • Price/Sales 2,678.30
  • Price/Cash Flow N/A
  • Price/Book 4.14
Trade IOVA with:

Options Overview Details

View History
  • Implied Volatility 85.30% ( +3.34%)
  • Historical Volatility 88.95%
  • IV Percentile 28%
  • IV Rank 16.93%
  • IV High 320.56% on 08/07/24
  • IV Low 37.36% on 08/15/24
  • Put/Call Vol Ratio 0.17
  • Today's Volume 2,227
  • Volume Avg (30-Day) 9,433
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 189,350
  • Open Int (30-Day) 184,910

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.33
  • Number of Estimates 7
  • High Estimate -0.25
  • Low Estimate -0.45
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +28.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.11 +63.99%
on 08/05/24
12.50 -6.72%
on 08/23/24
+2.70 (+30.13%)
since 07/30/24
3-Month
7.11 +63.99%
on 08/05/24
12.50 -6.72%
on 08/23/24
+2.66 (+29.56%)
since 05/30/24
52-Week
3.21 +263.24%
on 10/19/23
18.33 -36.39%
on 02/28/24
+5.54 (+90.52%)
since 08/29/23

Most Recent Stories

More News
Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years?

This company's new cancer therapy is producing remarkable results, but the company is losing money at a frightening pace.

IOVA : 11.66 (+2.46%)
This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock

It could demonstrate a few capabilities that no other biotech has as of yet.

IOVA : 11.66 (+2.46%)
Why Iovance Biotherapeutics Shares Are Soaring Today

The biopharma company is proving its recently approved cancer therapy is marketable.

IOVA : 11.66 (+2.46%)
Iovance Biotherapeutics: Q2 Earnings Snapshot

Iovance Biotherapeutics: Q2 Earnings Snapshot

IOVA : 11.66 (+2.46%)
10 Best Small and Mid-Cap Stocks to Consider Buying in August

A shift in market dynamics could favor these 10 growth stocks.

IOVA : 11.66 (+2.46%)
DKNG : 34.50 (+1.80%)
KTOS : 22.94 (+1.59%)
RKLB : 6.27 (+0.64%)
ACHR : 3.40 (-3.95%)
AVAV : 203.76 (+0.07%)
ALRM : 59.54 (-0.42%)
HLIT : 14.45 (-1.43%)
IRDM : 25.80 (-0.39%)
CRSP : 47.72 (+0.36%)
Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell?

Find out how concerned investors should be about setbacks for this company's revolutionary new cancer therapies.

MRK : 118.45 (+0.84%)
PIPR : 272.70 (+1.62%)
SF : 88.14 (+1.33%)
IOVA : 11.66 (+2.46%)
Why Iovance Biotherapeutics Stock Stumbled Today

One pundit warns of apparent manufacturing issues with the company's melanoma drug.

PIPR : 272.70 (+1.62%)
IOVA : 11.66 (+2.46%)
Life May Soon Get Easier for (Some) Biotech Stocks. Here's Why.

The Federal Reserve's fight against inflation may soon yield financial benefits.

XBI : 101.26 (+0.35%)
VKTX : 64.12 (+2.35%)
IOVA : 11.66 (+2.46%)
Is Iovance Biotherapeutics a Millionaire Maker?

This biotech's future is bright, but how good could it get for investors?

GILD : 79.00 (-0.57%)
IOVA : 11.66 (+2.46%)
Is It Too Late to Buy Iovance Biotherapeutics Stock?

The stock is down more than 50% from its 52-week high.

IOVA : 11.66 (+2.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own...

See More

Key Turning Points

3rd Resistance Point 12.24
2nd Resistance Point 11.97
1st Resistance Point 11.81
Last Price 11.66
1st Support Level 11.38
2nd Support Level 11.11
3rd Support Level 10.95

See More

52-Week High 18.33
Fibonacci 61.8% 12.55
Last Price 11.66
Fibonacci 50% 10.77
Fibonacci 38.2% 8.99
52-Week Low 3.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar